The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
ELN 2024 recommendations: Genetic risk stratification in patients with AML receiving less-intensive therapies
|
The 2017 and 2022 ELN risk classifications for patients with AML were not adequately validated in patients treated with less-intensive therapies. A new ELN 2024 genetic risk classification for stratifying prognostic outcomes in these patients was published by Dohner et al. in Blood.1 |
| Key learnings |
| Patients in the favorable-risk category with IDH-mutant AML receiving AZA + IVO had a median OS of >24 months, while those in the adverse-risk category with TP53 mutation had a median OS of 5–8 months. |
| TP53 mutations were consistently associated with unfavorable outcomes following treatment with HMA or HMA + VEN combination. DDX41 mutations were related to favorable outcomes following both HMA monotherapy and VEN-based combination therapies. |
| Patients with AML and MR mutations responded to HMA and VEN therapy; MR mutations in the presence of signaling gene mutations were associated with inferior prognosis. |
| The ELN 2024 recommendations on genetic risk stratification can help guide treatment in patients with AML receiving less-intensive therapies. However, further validation in clinical trials and real-world studies is needed. |
Abbreviations: AML, acute myeloid leukemia; AZA, azacitidine; DDX41, DEAD-box helicase 41; ELN, European LeukemiaNet; HMA, hypomethylating agent; IDH, isocitrate dehydrogenase; IVO, ivosidenib; MR, myelodysplasia-related; OS, overall survival; TP53, tumor protein p53; VEN, venetoclax.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
